PL376147A1 - Inhibitory białka regulującego transbłonowe przewodzenie w mukowiscydozie oraz ich zastosowania - Google Patents

Inhibitory białka regulującego transbłonowe przewodzenie w mukowiscydozie oraz ich zastosowania

Info

Publication number: PL376147A1
Authority: PL; Poland
Prior art keywords: cystic fibrosis; protein inhibitors; fibrosis transmembrane; conductance regulator; transmembrane conductance
Prior art date: 2002-09-30

Application number

PL03376147A

Other languages

English (en)

Inventor

Alan Verkman

Tonghui Ma

Original Assignee

The Regents Of The University Of California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-30

Filing date

2003-09-30

Publication date

2005-12-27

2002-09-30 Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en

2003-09-30 Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California

2005-12-27 Publication of PL376147A1 publication Critical patent/PL376147A1/pl

Links

102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title 1
229940121649 protein inhibitor Drugs 0.000 title 1
239000012268 protein inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Oncology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL03376147A 2002-09-30 2003-09-30 Inhibitory białka regulującego transbłonowe przewodzenie w mukowiscydozie oraz ich zastosowania PL376147A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/262,573 US20040063695A1 (en)	2002-09-30	2002-09-30	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US48025303P	2003-06-20	2003-06-20

Publications (1)

Publication Number	Publication Date
PL376147A1 true PL376147A1 (pl)	2005-12-27

Family

ID=32044981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03376147A PL376147A1 (pl)	2002-09-30	2003-09-30	Inhibitory białka regulującego transbłonowe przewodzenie w mukowiscydozie oraz ich zastosowania

Country Status (13)

Country	Link
EP (1)	EP1549321A4 (pl)
JP (1)	JP4977319B2 (pl)
KR (1)	KR20050061501A (pl)
CN (1)	CN100356922C (pl)
AP (1)	AP2005003292A0 (pl)
AU (1)	AU2003277162C1 (pl)
BR (1)	BR0314943A (pl)
CA (1)	CA2500498C (pl)
EA (1)	EA009847B1 (pl)
MX (1)	MXPA05003366A (pl)
NZ (1)	NZ538809A (pl)
PL (1)	PL376147A1 (pl)
WO (1)	WO2004028480A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
EP2142498A2 (en)	2007-04-02	2010-01-13	Institute for Oneworld Health	Cftr inhibitor compounds and uses thereof
HUE028426T2 (en) *	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EP2279029A2 (en) *	2008-03-25	2011-02-02	The Regents of the University of California	Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
WO2009131957A2 (en)	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en)	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
JP2012503005A (ja) *	2008-09-19	2012-02-02	インスティテュートフォアワンワールドヘルス	イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
EP2490696A1 (en) *	2009-10-20	2012-08-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
US20110251253A1 (en)	2010-03-25	2011-10-13	Vertex Pharmaceuticals Incorporated	Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
HRP20160682T1 (hr)	2010-04-07	2016-07-29	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CA2808501A1 (en)	2010-08-23	2012-03-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
CN102133402B (zh) *	2011-03-24	2013-06-12	首都医科大学附属北京同仁医院	囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用
US9056862B2 (en)	2011-05-10	2015-06-16	National University Corporation Kobe University	Thioxothiazolidine derivative having Ras function inhibitory effect
IN2014KN00885A (pl)	2011-11-08	2015-10-02	Vertex Pharma
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
LT3470063T (lt)	2012-11-02	2025-02-10	Vertex Pharmaceuticals Incorporated	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
FR2999191B1 (fr)	2012-12-12	2016-02-05	Lesaffre & Cie	Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
TWI735416B (zh)	2014-10-06	2021-08-11	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
CN104398509B (zh) *	2014-11-13	2017-01-11	四川大学华西第二医院	CFTR抑制剂CFTRinh-172在制备防治白血病细胞介导的疾病的药物中的应用
CN104788423B (zh) *	2015-03-13	2016-10-26	成都理工大学	一种新的囊性纤维化跨膜传导调节因子抑制剂
JP6894902B2 (ja)	2015-12-24	2021-06-30	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｃｆｔｒ制御因子及びこの使用方法
CN110267948B (zh)	2016-12-09	2023-12-08	弗特克斯药品有限公司	囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
KR102716244B1 (ko)	2017-12-08	2024-10-14	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
CN114007623A (zh) *	2019-06-12	2022-02-01	加利福尼亚大学董事会	治疗胆汁酸性腹泻的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL108962A (en) *	1989-12-21	1996-12-05	Lilly Co Eli	Use of hydroxybenzyl substituted sulfur containing heterocyclic derivatives a process for their preparation and pharmaceutical compositions containing them
AU1090795A (en) *	1993-11-12	1995-05-29	Cell Therapeutics, Inc.	Method for preventing tissue injury from hypoxia
US6423708B1 (en) *	1996-09-30	2002-07-23	Pfizer Inc	Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) *	1996-09-30	2003-05-15	Пфайзер Інк.	Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
WO2000010573A1 (en) *	1998-08-21	2000-03-02	Viropharma Incorporated	Compounds, compositions and methods for treating or preventing viral infections and associated diseases
US6484397B1 (en) *	2000-07-11	2002-11-26	Corning Incorporated	Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) *	2001-04-23	2002-05-02	Bailey Thomas R.	Compounds, compositions and methods for treating or preventing viral infections and associated diseases

2003
- 2003-09-30 AU AU2003277162A patent/AU2003277162C1/en not_active Ceased
- 2003-09-30 CA CA2500498A patent/CA2500498C/en not_active Expired - Fee Related
- 2003-09-30 PL PL03376147A patent/PL376147A1/pl not_active Application Discontinuation
- 2003-09-30 WO PCT/US2003/031005 patent/WO2004028480A2/en not_active Ceased
- 2003-09-30 NZ NZ538809A patent/NZ538809A/en not_active IP Right Cessation
- 2003-09-30 JP JP2004540305A patent/JP4977319B2/ja not_active Expired - Fee Related
- 2003-09-30 KR KR1020057005551A patent/KR20050061501A/ko not_active Abandoned
- 2003-09-30 EA EA200500583A patent/EA009847B1/ru not_active IP Right Cessation
- 2003-09-30 BR BR0314943-9A patent/BR0314943A/pt not_active IP Right Cessation
- 2003-09-30 EP EP03798805A patent/EP1549321A4/en not_active Withdrawn
- 2003-09-30 MX MXPA05003366A patent/MXPA05003366A/es active IP Right Grant
- 2003-09-30 AP AP2005003292A patent/AP2005003292A0/xx unknown
- 2003-09-30 CN CNB038233665A patent/CN100356922C/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20050061501A (ko)	2005-06-22
EP1549321A2 (en)	2005-07-06
JP2006503853A (ja)	2006-02-02
EA009847B1 (ru)	2008-04-28
WO2004028480A2 (en)	2004-04-08
AU2003277162C1 (en)	2009-12-24
NZ538809A (en)	2008-06-30
WO2004028480A3 (en)	2004-07-01
CN1684686A (zh)	2005-10-19
CA2500498C (en)	2012-08-21
AP2005003292A0 (en)	2005-06-30
AU2003277162A1 (en)	2004-04-19
CA2500498A1 (en)	2004-04-08
CN100356922C (zh)	2007-12-26
EP1549321A4 (en)	2007-05-23
JP4977319B2 (ja)	2012-07-18
BR0314943A (pt)	2005-08-02
AU2003277162B2 (en)	2009-07-16
MXPA05003366A (es)	2005-10-05
EA200500583A1 (ru)	2005-12-29

Legal Events

Date	Code	Title	Description
2012-03-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
AP2005003292A0 (en)	2005-06-30	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2003228393A1 (en)	2003-10-13	Ehanced protein expression in bacillus
WO2004040000A9 (en)	2009-08-27	G protein coupled receptors and uses thereof
PL375447A1 (pl)	2005-11-28	Inhibitory kinaz białkowych i ich zastosowania
AU2003270341A1 (en)	2004-03-29	Modified asialo-interferons and uses thereof
HUP0301063A3 (en)	2011-05-30	Benzoic-acid isononylesters and applying them
AU2003280084A8 (en)	2004-04-30	Protein arrays and uses thereof
AUPS238502A0 (en)	2002-06-13	Cystic echinococcosis protein and uses therefor
AU2003222225A1 (en)	2003-09-09	Receptors and membrane-associated proteins
AU2003300815A8 (en)	2004-06-30	Protein modification and maintenance molecules
AU2003268023A8 (en)	2004-02-09	Protein modification and maintenance molecules
HK1079695A (en)	2006-04-13	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2002348834A8 (en)	2003-06-23	Method and system providing user mobility in a mobile-ip-network by means of a personal ip address
AU2003301112A1 (en)	2004-07-14	Hand and fingernail cleaning apparatus
AU2003231981A8 (en)	2003-10-13	Protein modification and maintenance molecules
AU2003239871A8 (en)	2003-12-12	Protein modification and maintenance molecules
AU2003280992A1 (en)	2004-02-02	Novel proteins and use thereof
AU2003291426A8 (en)	2004-06-03	Gp64-pseudotyped vectors and uses thereof
AU2003292774A1 (en)	2004-07-22	Novel proteins and use thereof
AU7080601A (en)	2002-01-30	Activation of the cystic fibrosis transmembrane conductance regulator chloride channel
AU2003260487A8 (en)	2003-10-20	Novel pancortin-pablo protein interactions and methods of use thereof
AU2003202650A1 (en)	2003-12-02	Cystic echinococcosis protein and uses therefor
EP1549951A4 (en)	2006-08-09	SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF
EP1699809A4 (en)	2009-10-21	PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
AU2003279829A1 (en)	2004-05-04	Protein modification and maintenance molecules